Erste Asset Management GmbH acquired a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,528 shares of the company's stock, valued at approximately $597,000.
Several other large investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its stake in shares of Progyny by 12,579.4% during the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock valued at $41,777,000 after purchasing an additional 2,472,983 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Progyny by 1,576.0% during the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock valued at $42,991,000 after purchasing an additional 2,412,068 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Progyny by 120.8% in the second quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock valued at $37,436,000 after buying an additional 715,900 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Progyny by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company's stock valued at $36,676,000 after buying an additional 254,725 shares during the period. Finally, Millennium Management LLC lifted its holdings in Progyny by 77.8% in the second quarter. Millennium Management LLC now owns 535,962 shares of the company's stock valued at $15,334,000 after buying an additional 234,590 shares during the period. 94.93% of the stock is owned by institutional investors.
Progyny Price Performance
Shares of PGNY traded up $0.12 during trading hours on Thursday, hitting $15.00. The company's stock had a trading volume of 1,294,210 shares, compared to its average volume of 1,401,224. The company has a market cap of $1.28 billion, a price-to-earnings ratio of 25.66, a PEG ratio of 1.71 and a beta of 1.35. The business has a 50 day simple moving average of $15.71 and a two-hundred day simple moving average of $21.93. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). The firm had revenue of $286.63 million for the quarter, compared to analysts' expectations of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. Progyny's revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.16 EPS. Research analysts predict that Progyny, Inc. will post 0.58 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on PGNY. Bank of America dropped their price objective on shares of Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of Progyny in a report on Tuesday, October 1st. JMP Securities lowered shares of Progyny from an "outperform" rating to a "market perform" rating in a report on Thursday, September 19th. BTIG Research lowered shares of Progyny from a "buy" rating to a "neutral" rating in a report on Wednesday, August 7th. Finally, Truist Financial reaffirmed a "hold" rating and issued a $19.00 target price (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $25.00.
Check Out Our Latest Analysis on PGNY
Progyny Company Profile
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
